Cara Therapeutics

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cara Therapeutics reports solid Q4 earnings amidst growth opportunities

Cara Therapeutics showcased strong revenue growth and positive feedback on KORSUVA injection sales in Q4 2022.
While facing challenges such as demand instability and regulatory uncertainties, the company remains confident in its growth prospects.
Strategic investments, milestone anticipation, and financial stability position Cara well for future value creation and market expansion.

Cara Therapeutics reports strong Q1 revenue, optimistic about pipeline growth

Cara Therapeutics delivered solid revenue in Q1 2023 driven by the successful launch of KORSUVA and Kapruvia. While facing increased operating expenses, the company remains optimistic about its pipeline's potential. Strategic focus on KORSUVA's success and ongoing R&D efforts position Cara for future growth.

Cara Therapeutics reports solid Q2 earnings amidst regulatory uncertainties

Cara Therapeutics posted strong financial performance in Q2 2023, driven by robust net sales and cash reserves, with a focus on maximizing shareholder value.
The company faces challenges related to potential CMS changes and European market dynamics but sees opportunities in international expansion and regulatory engagement.
Overall, Cara Therapeutics remains optimistic about the commercial prospects of its key products and pipeline, aiming for sustained growth and market leadership.

Cara Therapeutics extends cash runway, faces funding challenges ahead

Cara Therapeutics reports strong financials with extended cash runway. Progress in late-stage programs and successful monetization of royalties. Facing challenges with funding limitations and uncertainties around data releases.

Cara Therapeutics extends cash runway to 2026 amidst revenue challenges

Cara Therapeutics strategically focused on NP and oral DSK programs to drive growth.
Strong demand for KORSUVA injection but challenges from reimbursement changes.
Confidence in NP program and potential partnerships signal future opportunities.
Financially extended runway to 2026 but facing liquidity challenges with $1.8 million cash.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Small-cap biotech Cara Therapeutics Inc (NASDAQ: CARA) is trading to its highest level since early April after it released the results of a Phase 3 trial for its lead candidate Korsuva.

Cara Therapeutics Rallies On Positive Clinical Readout For Pruritis Drug

The biotech reported great late-stage clinical results for its lead drug candidate.

Why Cara Therapeutics Stock Is Soaring Today

Cara Therapeutics Inc. shares jumped on Wednesday after the firm announced topline data from its late-stage trial in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP).

What This Cara Therapeutics Late-Stage Study Could Mean for Chronic Kidney Disease

Shares of Cara Therapeutics Inc., CARA, -0.39% a biotech developing treatments for itchiness, rose 12.6% in premarket trade Wednesday after the company reported that dialysis patients experiencing itchiness who were given its Korsuva injection showed statistically significant improvement compared with those on placebo.

Cara Therapeutics stock up 12.6% after company announces positive Phase 3 data for itchiness treatment

Charlotte's Web Holdings, Inc.

Comfort Systems USA

These companies don't seem to have much in common. But they could all deliver big gains for investors.

Three Top Small-Cap Stocks to Buy Right Now.

Editas Medicine

Viking Therapeutics

They're risky. You'll have to wait years before any significant revenue comes in.

3 Small-Cap Biotech Stocks You Can Buy Right Now

Cara Therapeutics, Inc. (CARA) CEO Dr.

GW Pharmaceuticals

Both of these biotech stocks have tremendous momentum. Which is more likely to deliver bigger returns in the future?

Cara Therapeutics vs. GW Pharmaceuticals

This small biotech expects to announce results from two clinical studies in 2019.

Why Cara Therapeutics Stock Jumped 15.1% in March

Innoviva

TG Therapeutics

These three biotech stocks are worth buying this month.

3 Top Biotech Stocks to Buy  in April

Genfit - ADR

They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.

3 Top Small-Cap Biotech Stocks for Aggressive Investors

The pharma company announced full-year 2018 operating results and reiterated the road map for the year ahead.

Here's Why Cara Therapeutics Stock Rose as Much as 13.9% Today

News for Cara Therapeutics Stock (CARA)